{
  "Cancer Histology Type (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        803, 
        812
      ]
    }
  ], 
  "Comments Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1031, 
        1051
      ]
    }
  ], 
  "Final Diagnosis Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        703, 
        730
      ]
    }
  ], 
  "Laterality (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        733, 
        738
      ]
    }
  ], 
  "Nature of Specimen Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        646, 
        672
      ]
    }
  ], 
  "Neoplasm Behaviour (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        786, 
        794
      ]
    }
  ], 
  "Organ/Body Structure (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        739, 
        745
      ]
    }
  ], 
  "__text": "MSH|^~\\&|PATHLAB_LIS|HOSPITAL 2^9999^MOH|PIMS|CCO-OCR|20160503195200|0042DFD04504A8D0141205796D4D206EFD293C51|ORU^R01|9999999999999999|P|2.5|\nPID|1||^^^^CMR^Peterborough Regional Health Centre&9999&MOH~^^^^RMR^Peterborough Regional Health Centre&9999&MOH~99999999^^^^MRN^HOSPITAL 2&9999&MOH~9999999999&LH&ON^^^^JHN||XXXXX^XXXXX^XXX||99999999|F|||99999 XXXXXXX 9 XX#9^^XXXXXXXXX^XX^X9X 9X9^999|||||||||||||||||||N|\nOBR|1||S16-27563|11529-5^Surgical Pathology Study Report^LN^P^Pathology^L|||201604280000|||85113^XXX^XXXXXX||||201604291019|&Consult blocks:2A 16-S4874|99999^XXX^XXXXXX||||Y||201605031952||LS|F|||||||99999^XXXXXXXXX^XXXXXXX|\n\n\n\n\n\n\n\nPath report.site of origin\n\nConsult blocks:2A 16-S4874\n\n\nPath report.final diagnosis\n\n\nRight breast (excision without wire localization):\n \nInvasive mammary carcinoma, please see synoptic breast biomarker immunohistochemistry reported below.\n\nNote: Since this is a triple negative carcinoma with cold ischemic time over 5.5 hours, a repeat biomarkers on the core biopsy is advised.\n\n\n\nPath report.comments\n\nBIOMARKER STUDIES\n\nBlock / Tumor Stained:   Block: PRHC 16-S 4874-2/A\n   -Invasive breast carcinoma\nTEST(S) PERFORMED\nEstrogen Receptor (ER) Status:\n--NEGATIVE\n---Internal control cells present and stain as expected\n-Test Type:   --Laboratory-developed test\n-Primary Antibody:   --SP1\nProgesterone Receptor (PgR) Status:\n--NEGATIVE\n---Internal control cells present and stain as expected\n-Test Type:   --Laboratory-developed test\n-Primary Antibody:   --16\nHER2 by Immunohistochemistry (IHC):\n--NEGATIVE (Score 0)\n-Uniform Intense Complete Membrane Staining (%): 0\n-Test Type:   --Laboratory-developed test\n-Primary Antibody:   --4B5\nMETHODS\nCold Ischemia and Fixation Times:   Do not meet requirements specified in latest version of the ASCO / CAP Guidelines\nFixative:   Formalin\n\n\n\n\n"
}